de Medeiros C R, Moreira V A, Pasquini R
Bone Marrow Transplantation Service, Hospital de Clinicas/UFPr. Curitiba, PR, Brazil.
Bone Marrow Transplant. 2000 Aug;26(4):443-4. doi: 10.1038/sj.bmt.1702538.
Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality after allogeneic transplant. Interstitial pneumonia (IP) is the most common manifestation of CMV in BMT patients, with a 30-48% mortality rate despite adequate treatment. Most CMV infection occurs in the first 100 days. However, prolonged ganciclovir (GCV) prophylaxis has favored the occurrence of late CMV IP, probably by inhibition of the development of CMV-specific T cell lymphocyte responses. We report the case of a patient treated with an allogeneic BMT who received pre-emptive GCV until day +100 because of CMV-positive antigenemia. He developed a CMV IP on day +811 post BMT, which responded to treatment. We intend to alert clinicians that even at long-term (>1 year) post-BMT, CMV is a possible cause of IP in high-risk patients.
巨细胞病毒(CMV)感染是异基因移植后发病和死亡的重要原因。间质性肺炎(IP)是骨髓移植(BMT)患者中CMV最常见的表现形式,尽管进行了充分治疗,死亡率仍为30%-48%。大多数CMV感染发生在移植后的前100天内。然而,长期使用更昔洛韦(GCV)进行预防可能会促进晚期CMV-IP的发生,这可能是由于抑制了CMV特异性T淋巴细胞反应的发展。我们报告了1例接受异基因BMT治疗的患者,因其CMV抗原血症阳性,在移植后第100天之前接受了抢先性GCV治疗。他在BMT后第811天发生了CMV-IP,治疗后有反应。我们希望提醒临床医生,即使在BMT后长期(>1年),CMV仍是高危患者发生IP的可能原因。